Navigation Links
Richard A. Schatz, M.D. Joins Cardium's Scientific Advisory Board
Date:5/1/2008

r. For more information about Cardium's Tissue Repair Company subsidiary, please visit http://www.t-r-co.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that our scientific advisors and other key personnel will effectively assist in the development of our business or product candidates, that our products or product candidates will prove to be sufficiently safe and effective or will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive, that results or trends observed in one clinical study will be reproduced in subsequent studies, that third parties on whom we depend will behave as anticipated, or that necessary regulatory approvals will be obtained. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, our limited experience in the development, testing and marketing of therapeutic hypothermia devices and whether our efforts to launch new devices and systems will be successful or completed within the time frames contemplated, risks and uncertainties that are inherent in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the
'/>"/>

SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Richard Schulz Receives the Coveted GCPj Award for Best Clinical Researcher of the Year
2. Senior Research Analyst Richard Evans Joins AVOS Life Sciences
3. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
4. Clinical and Economical Considerations For IV Push Drug Delivery by Industry Expert Richard Rosenfeld Is Now Accessible on Expert411.com for Media and Professional Use
5. Genetic Immunity Announces the Appointment of Richard B. Pollard, M.D. as Chief Medical Officer
6. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
7. Mr. Richard Decker Appointed Technical Director of Edgewood Chemical Biological Center
8. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
9. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
10. Hank Plain Joins Morgenthaler Ventures as Partner
11. Legendary Earvin Magic Johnson Joins AFL/Signalife Cardiovascular Protection Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... (PRWEB) October 24, 2014 SonaCare ... focused ultrasound (HIFU) technology, announced that its Board ... as Chief Executive Officer, President and member of ... Dr. Carol will take-on expanded responsibilities within the ... as well as overseeing commercialization, manufacturing and finance. ...
(Date:10/25/2014)... 25, 2014 Berkshire Corporation, the ... to announce the release of the ValuSeal® IonX™ ... of contamination containment in critical processing applications. , ... higher cleanroom environments, ValuSeal® IonX™ is a laser ... wiper that continues Berkshire’s innovative focus on meeting ...
(Date:10/25/2014)... and NEW YORK ... Inc. (OTCQB: ACCPD), formerly Access Pharmaceuticals, Inc. (ACCP), ... areas, announced it has implemented a 1-for-50 reverse ... opening of trading on Friday, October 24, 2014. ... basis under new CUSIP number 72754H109 and temporary ...
(Date:10/25/2014)... LONDON , October 24, 2014 ... CytRx Corporation (NASDAQ: CYTR ), Vertex Pharmaceuticals ... (NASDAQ: ALXN ), Peregrine Pharmaceuticals Inc. (NASDAQ: ... Free research on these five companies can be accessed ... on Thursday, October 23, 2014, ended on a positive ...
Breaking Biology Technology:SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5
... ATLANTA and BOSTON, March 17 Alimera Sciences,and ... Xetra: PSI) today announced that,they have amended their ... companies, Phase III investigative treatment for,diabetic macular edema ... equity in the future profits of Medidur FA ...
... Validates Platform Designed to Deliver Electronic X-ray-Based, ... Minimally Shielded Clinical Settings, SUNNYVALE, Calif., ... it has received expanded clearance from the ... Axxent(R) Electronic Brachytherapy System, a,proprietary technology platform ...
... inflammation poised to ... control., MENLO PARK, Calif., March 17 Apieron, ... system has received,clearance to market by the U.S. Food ... exhaled nitric oxide (eNO), which is a,well-established indicator of ...
Cached Biology Technology:Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement 2Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement 3Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement 4FDA Clears Expanded Use of Xoft's Axxent(R) Electronic Brachytherapy System for all Radiation Therapy Indications 2Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management 2Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management 3
(Date:10/16/2014)... Virus causes severe respiratory tract infections and worldwide ... Scientists at VIB and Ghent University have succeeded ... this common virus infection. , Xavier Saelens ... paves the way for the development of a ... that causes suffering in numerous small children and ...
(Date:10/15/2014)... WASHINGTON, N.Y. , Oct. 15, 2014 /PRNewswire/ ... technology solutions for home and community-based care, today ... benefits of implementing Sandata,s Santrax® Electronic Visit Verification™ ... Care Services is a home health company founded ... Texas . The ...
(Date:10/15/2014)... The German Gauß-Allianz has admitted Johannes Gutenberg University ... the Rhineland-Palatinate science hub continues to maintain a ... computing. , "The acceptance of Johannes Gutenberg ... Gauß-Allianz is a milestone in the national and ... support. The state of Rhineland-Palatinate can be proud ...
Breaking Biology News(10 mins):New perspectives for development of an RSV vaccine 2Sandata Announces Case Study with Quality Care Services, Inc. 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... major greenhouse gas carbon dioxide (CO2) from industrial plants ... is on the verge of becoming a commercial reality. Several ... U.S. are leading the way, according to an article in ... the American Chemical Society. Alex Scott, C&EN,s senior editor ...
... WEST BEND, Wis. , Nov. 6, 2013 ... organization focused on driving value for clients through technology and ... collaboration platform to help manage the execution of ... The Spaulding Clinical team is using ...
... squishy gel that when compressed like at a ... material could someday deliver medications when and where osteoarthritis ... ACS journal Biomacromolecules . Xinqiao Jia, Chandran ... few decades, researchers have been developing a variety of ...
Cached Biology News:Projecis Cloud-based Collaboration Platform Selected by Spaulding Clinical to Manage Phase I Clinical Trial Projects and Timelines 2Projecis Cloud-based Collaboration Platform Selected by Spaulding Clinical to Manage Phase I Clinical Trial Projects and Timelines 3
MAb to Vasopressin Preservative: NaN3...
... Anti-AP-2 α, clone 8G8/5 GenBank Accession ... made human AP-2alpha/gamma fusion protein corresponding to ... 278-450 of human AP-2γ Formulation: 0.1M Tris-glycine, ... before the addition of glycerol to 30% ...
Mouse monoclonal [1C6/2] to Rad17 ( Abpromise for all tested applications). entrezGeneID: 5884 SwissProtID: Q9UPF5...
MMP-2 / MMP-9 Inhibitor IV is a potent, selective, slow binding and mechanism based inhibitor of human gelatinases. • Molecular weight: 306.4 • Molecular Formula: C(15)H(14)O(3)S(2). &bul...
Biology Products: